KOSUNI KOREA
Korean News in English
Business

Trump's Economic Strategy: U.S. Corporate Responses and Case Studies

Published September 20, 2026 · 3 views
Trump's Economic Strategy: U.S. Corporate Responses and Case Studies

The Trump administration's Section 301 investigation and tariff policies have prompted U.S. and Korean companies to develop various response strategies. SH Energy Chemicals became the first domestic company to complete full reimbursement of reciprocal tariffs under the Trump policy, while small and medium enterprises (SMEs) saw tariffs reduced from 50% to 15%. U.S. companies are responding through production base reallocation and global supply chain restructuring, with industry associations like the Medical Device Association and consulting firms PwC and Deloitte offering strategy seminars and reports for policy analysis. K-pharmaceutical and biotech companies are focusing on building independent technological competitiveness to overcome tariff barriers.

Changes in Trump Administration Tariff Policies

The Trump administration implemented new tariff strategies through Section 301 investigations, requiring both U.S. and Korean firms to adapt. The Section 301 investigation served as an important indicator of trade policy shifts, with the U.S. using it as an economic pressure tool for countering China and addressing Iran.

트럼프 경제작전, 미국 기업의 대응 전략과 사례 설명 이미지

Korean Companies' Response Strategies

Korean companies have expanded their 'Tariff Response 119' to a broader 'Trade Response 119' strategy, preparing for various policy changes beyond tariffs. SH Energy Chemicals completed the first full tariff reimbursement among domestic firms under Trump policies, showcasing Korean companies' capability in tariff response.

For SMEs, there are cases where tariffs were reduced from 50% to 15%, achieved through government-business collaboration that eased tariff burdens and helped maintain competitiveness.

U.S. Companies' Response Strategies

U.S. companies are responding to tariff policy changes by reallocating production bases and restructuring global supply chains, aiming to increase domestic production and strengthen international trade competitiveness.

The Medical Device Association organized webinars targeting entry into the U.S. medical market, a strategic move to enhance competitiveness within the American market following tariff policy shifts. PwC and Deloitte released analytical reports on Trump's second term policies, offering strategies for companies to respond effectively.

K-Pharmaceutical and Biotech Companies' Strategy

K-pharmaceutical and biotech companies are focusing on building independent technological competitiveness to overcome tariff barriers. U.S. tariff barriers are viewed not as a short-term 'shower' but as structural 'climate change,' leading to strategies emphasizing productivity improvement and technological innovation.

Yulchon Law Firm hosted seminars on trade policies and ITC (International Trade Commission) and economic sanctions response strategies for the Trump 2.0 era, supporting companies in adapting to policy changes.

Background of Trump's Economic Warfare

The Trump administration shifted from military responses to Iran toward economic warfare. This included approving private sector operations against ransomware organizations with a $100,000 deposit requirement, reflecting the U.S.'s strategic move to reestablish relations with Iran through economic pressure.

Pro-Trump governments in Iran are developing plans to gain global logistics dominance post-war as part of countering China, aiming to strengthen U.S. competitiveness against China.

The Importance of Corporate Diplomacy

In an era where power often outweighs law, corporate diplomacy has emerged as a survival strategy. This reflects the increasing complexity of international relations and the need for companies to collaborate with governments to adapt to global trade environments.

Investigating Causes Behind Tariff Policy Changes

The Trump administration's tariff policy changes aimed at economic pressure against China and addressing Iran. Section 301 investigations served as a key indicator of trade policy shifts, signaling the U.S.'s effort to gain an edge in competition with China.

Viewing U.S. tariff barriers not as short-term 'shower' but structural 'climate change' indicates that companies must respond through productivity enhancement and technological innovation rather than simple policy adjustments.

Response Strategies and Safety Information

Companies are developing various strategies to adapt to tariff policy changes. SH Energy Chemicals' case of securing full tariff reimbursement demonstrates effective corporate capability in tariff response.

For SMEs, government-business collaboration has successfully reduced tariff burdens, contributing to maintaining competitiveness. Seminars and reports by the Medical Device Association and PwC/Deloitte provide essential information for companies to maintain competitiveness in global trade environments.

Information to Verify

Accurate verification of Trump administration tariff policy changes is crucial. Section 301 investigations serve as a key indicator of trade policy shifts, with the U.S. using them as economic pressure tools against China and for addressing Iran.

The case of reduced tariff burdens on SMEs through government-business collaboration demonstrates how appropriate responses to policy changes can contribute to corporate growth.

Frequently Asked Questions

What is the impact of Trump administration tariff policy changes on Korean companies?

Korean companies have expanded their 'Tariff Response 119' to a broader 'Trade Response 119' strategy, preparing for various policy changes beyond tariffs.

What does SH Energy Chemicals' completion of full tariff reimbursement signify?

SH Energy Chemicals became the first domestic company to complete full reimbursement of reciprocal tariffs under Trump policies, showcasing Korean companies' capability in tariff response.

What strategies are K-pharmaceutical and biotech companies using to overcome tariff barriers?

K-pharmaceutical and biotech companies focus on building independent technological competitiveness to overcome tariff barriers. U.S. tariff barriers are viewed as structural 'climate change,' requiring productivity improvement and technological innovation as key responses.

Frequently Asked Questions

Trump administration's tariff policy changes reflect significant shifts in U.S. economic strategy, prompting both U.S. and Korean companies to develop various response strategies. The case of SH Energy Chemicals securing full tariff reimbursement and SMEs reducing tariffs through government-business collaboration demonstrate successful cooperation. Seminars and reports by the Medical Device Association and PwC/Deloitte support companies adapting to policy changes. K-pharmaceutical and biotech companies' focus on independent technological competitiveness has become a core strategy for overcoming tariff barriers.

Related Articles

You can view similar articles in one place.

View Related Articles

FAQ

What is the impact of Trump administration tariff policy changes on Korean companies?

Korean companies have expanded their 'Tariff Response 119' to a broader 'Trade Response 119' strategy, preparing for various policy changes beyond tariffs.

What does SH Energy Chemicals' completion of full tariff reimbursement signify?

SH Energy Chemicals became the first domestic company to complete full reimbursement of reciprocal tariffs under Trump policies, showcasing Korean companies' capability in tariff response.

What strategies are K-pharmaceutical and biotech companies using to overcome tariff barriers?

K-pharmaceutical and biotech companies focus on building independent technological competitiveness to overcome tariff barriers. U.S. tariff barriers are viewed as structural 'climate change,' requiring productivity improvement and technological innovation as key responses.

Korean Source

This article is an English localization of a Korean-language report from BlogScore. Original: 트럼프 경제작전, 미국 기업의 대응 전략과 사례